Fig. 5.
Systemic MV-Edm therapy by intravenous administration into mice bearing ARH-77 myeloma xenografts.
Mice bearing ARH-77 myeloma xenografts were treated intravenously with a single dose (A) or 7 doses (B) of 107 pfu MV-Edm/100 μL (●) or UV-inactivated MV-Edm (○). The number of mice in each treatment group that received 1 dose or 7 doses of virus was 4 and 6, respectively. For both dosing regimes, the difference in tumor growth between the treatment group and the control group was significantly different (P = .0001).
